Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Robert Barrow_2023
VIEWPOINTS

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

Shots:Robert spoke about the topline data from the P-II study evaluating Lysergide. The data was unleashed by MindMed collaborators at the University Hospital Basel and the University Hospital of PsychiatryThe data demonstrated significant, rapid, durable and beneficial effects of Lysergide and its potential to mitigate symptoms of MDD.  He also discussed how these…
August 29, 2023

Read more

PharmaShots Interview MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin
VIEWPOINTS

PharmaShots Interview: MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin

In an interview with PharmaShots, Robert Barrow, CEO at MindMed shared his views on the Study Acute Effects of Lysergic Acid Diethylamide vs. Psilocybin in Healthy SubjectsShots:Robert spoke about the data from the peer-reviewed publication of a study comparing the acute effects of LSD and psilocybin in healthy subjectsRobert also emphasized the clinical results and significance of…
May 30, 2022

Read more